Aushon Expands Technology Portfolio for Biomarker Analysis

Share Article

Three key new patents are issued to Aushon for its Multiplex Platform.

Aushon BioSystems, a leading provider of products and services for multiplex quantitative detection of protein biomarkers, today announced that it has continued to build its patent portfolio with the issuance of three new patents.

Two of the patents relate to technology innovations utilized in the fabrication of multiplex protein panels commercialized as part of Aushon’s Cira™ biomarker platform. These patents cover technology used in the printing of complex protein arrays on a wide variety of substrates as well as the novel blocking process used to immobilize the biomolecules enabling the fabrication of highly precise and robust panels. The third patent relates to technology used in the Cirascan™ imaging system to increase the dynamic range for quantitative assays enabling detection of proteins at sub-picogram levels.

“These additional new patents speak to the extent of innovation and technology incorporated into Aushon’s multiplex platform which enable the precision and sensitivity that have been achieved by customers utilizing the Cira platform for their biomarker analysis,” said Susan Vogt, CEO of Aushon. “With the ability to simultaneously measure up to twelve biomarkers in each well of a 96-well plate in under two minutes, clinical researchers are able to generate tens of thousands of data points in a single day, enabling them to rapidly advance the development of new therapeutics and diagnostic tests.”

Added Pete Honkanen, Aushon’s founder and COO, “At the core of our technology is the ability to create an array through the precise deposition and immobilization of very small amounts of complex materials in a wide variety of formats. We continue to work with customers to find new ways to fully exploit the unique capabilities of our protein array fabrication technologies including high density arrays with thousands of features in a variety of formats ranging from slides to 384-well plates.”

About Aushon BioSystems

Aushon BioSystems, Inc. provides a comprehensive suite of multiplex immunoassay products and services for protein biomarker discovery, development, and analysis to leading pharmaceutical, biotechnology, academic, and diagnostic clients worldwide. Our unique combination of proprietary microarray printing, extensive biomarker content, and innovative Cira immunoassay platform delivers exceptional performance, quality, and reliability to accelerate preclinical and clinical biomarker research. Our customers, who include leading pharmaceutical companies and translational research centers, trust Aushon to supply the most reliable biomarker data available, accelerating the evaluation of potential drug candidates and advancing the use of biomarker profiles in therapeutics.

Media Contact

Bill Williams
Vice President, Sales and Marketing
Aushon BioSystems

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Susan Vogt
Visit website